The two companies also shared next steps in their drug testing regimens. The post Atai, Cybin Give Positive Psychedelic Drug Study Updates appeared first...
Atai Life Sciences has completed its Phase 1 study of VLS-01, an oral DMT for treatment-resistant depression (TRD). The post atai Life Sciences Completes...
A Michigan lawmaker has relaunched efforts to legalize psychedelic fungi and plants with the caveat that all psychedelic-related activity does not involve...
Psychedelic stocks are on the rise. Despite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness...
Cantor Fitzgerald, in reaction to the news, downgraded the stock. The post Seelos Downgraded After Phase 2 Trial Failure appeared first on Green Market...
The import to Filament’s Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and...
Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide. The post...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced top-line data demonstrating clinically meaningful treatment effects across multiple endpoints and a...
Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated...
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), closed its United States-only public offering raising approximately $2.25 million. The offering consisted...